Aldevron Breakthrough Blog: Research and Development

Combining Resources to Streamline and Standardize Therapies

Academics and manufacturing making processes better

Witnessing firsthand the growth of cell and gene therapy to progress more programs to the bedside is an exciting time in the biotechnology industry, particularly with new partnership approaches being developed. I was able to get an overview of one particular partnership during a podcast featuring Tom Foti, VP of Protein Business unit at Aldevron, and Kris Saha, Ph.D., Associate Professor of Biomedical Engineering, Medical History and Bioethics at the University of Wisconsin.

Read More

Podcast: Insights into the Editing of the Human Genome

Where Can Novel Nonviral Polymeric Delivery Agents Take Us?

Collaboration has always been an important part of scientific research and discovery, especially when you combine the resources of strategic partners in science, clinical, engineering and manufacturing.

Read More

100-Day Review – From Research to Clinic, and a Pet Project

Insider Insights Inspire Ideas

I’ve spent most of the last 30 years in marketing and sales for molecular biology research products. During that time, I’ve been responsible for software platforms and instrumentation, but my main focus has been on reagents and consumables – nucleic acid purification, PCR, cloning tools, and so forth.

Read More

The Benefits of Streamlining and Standardizing Plasmid DNA for Cell and Gene Therapies

Manufacturing standardization for cell and gene therapies (C&GT) has received increased focus in the last several years, spurred by the rapid exponential growth witnessed in this field. The resulting need for improved access to high-quality raw materials, including plasmid DNA, has made standardization integral to streamlining the development process for this biologic product category. 
Read More

The Pivotal Role of Plasmid DNA

Plasmid DNA has historically been key to the development of biologic drug manufacturing. Today, it plays a critical role in the production of next-generation cell and gene therapies and vaccines. With our nearly 23 years of plasmid DNA manufacturing expertise, Aldevron has helped facilitate the advance of these important therapeutics. We continue to invest in additional capacity and novel capabilities to support biopharma manufacturers into the future.
Read More